BLLN logo

BILLIONTOONE INC CL A

BLLNNASDAQ
πŸ† #1203 by market capEarnings Nov 4 Β· PostUS Equity
$114.19β–² $0.41 (+0.36%)
Latest quote
πŸ””
Track BLLN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.4%
7dβ–² 7.9%
14dβ–² 11.1%
30dβ–Ό 3.3%
ytdβ–² 39.4%
1yβ€”
🏦Market Cap
$5.39B
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
71.3%
High
πŸ’΅FCF Margin
8.3%
Moderate
βš–οΈP/S Ratio
13.2x
Elevated
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$113.16 – $115.20
52-Week Range
$61.96 – $150.44
Volume (shares)
23,647
Avg Volume (shares)
β€”
Shares Outstanding
47.2M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$305M
Last Q Revenue
$109M
P/E Ratio
139.5
P/S Ratio
13.2x
EPS (TTM)
$0.77
Dividend Yield
β€”
Dilution (1yr)
+2.4%
BLLN logo

BILLIONTOONE INC CL A

BLLN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$305Mβ–² +100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
68.3%β–² +28.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$16Mβ–Ό βˆ’134.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$16Mβ–Ό βˆ’133.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
45.8Mβ–² +2.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$387Mβ–² +$305M YoY
StockOtter Β· stockotter.space

About BILLIONTOONE INC CL A

BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
15 analysts
Strong Buy6
Buy6
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.